HZNP Horizon Therapeutics Public Limited Company Stock Quote

HZNP [NASD]

Horizon Therapeutics Public Limited Company

Healthcare | Drug Manufacturers - General | Ireland

Index	-	P/E	25.98	EPS (ttm)	3.65	Insider Own	0.40%	Shs Outstand	229.09M	Perf Week	4.97%
Market Cap	21.56B	Forward P/E	13.23	EPS next Y	7.17	Insider Trans	-55.33%	Shs Float	225.83M	Perf Month	-7.22%
Income	862.10M	PEG	1.95	EPS next Q	1.36	Inst Own	96.50%	Short Float	3.26%	Perf Quarter	4.03%
Sales	3.77B	P/S	5.72	EPS this Y	25.30%	Inst Trans	5.59%	Short Ratio	3.97	Perf Half Y	-9.24%
Book/sh	21.03	P/B	4.51	EPS next Y	20.65%	ROA	10.10%	Target Price	140.73	Perf Year	3.47%
Cash/sh	7.23	P/C	13.12	EPS next 5Y	13.30%	ROE	19.10%	52W Range	82.51 - 120.54	Perf YTD	-11.99%
Dividend	-	P/FCF	18.23	EPS past 5Y	33.30%	ROI	8.50%	52W High	-21.32%	Beta	1.14
Dividend %	-	Quick Ratio	3.30	Sales past 5Y	26.90%	Gross Margin	75.90%	52W Low	14.94%	ATR	3.89
Employees	1940	Current Ratio	3.60	Sales Q/Q	158.50%	Oper. Margin	23.80%	RSI (14)	51.53	Volatility	3.42% 4.50%
Optionable	Yes	Debt/Eq	0.53	EPS Q/Q	257.10%	Profit Margin	22.90%	Rel Volume	1.14	Prev Close	90.59
Shortable	Yes	LT Debt/Eq	0.53	Earnings	May 04 BMO	Payout	0.00%	Avg Volume	1.85M	Price	94.84
Recom	1.60	SMA20	4.73%	SMA50	-6.77%	SMA200	-8.38%	Volume	2,100,370	Change	4.69%

May-23-22

Initiated

SVB Leerink

Mkt Perform

$95

Mar-15-22

Initiated

Oppenheimer

Outperform

$140

Dec-08-21

Initiated

Wells Fargo

Overweight

$137

Nov-19-21

Upgrade

Goldman

Neutral → Buy

$168

Oct-07-21

Resumed

Jefferies

Buy

$132

Mar-22-21

Resumed

Morgan Stanley

Overweight

$103

Mar-12-21

Initiated

Wolfe Research

Outperform

$107

Sep-09-20

Initiated

JP Morgan

Overweight

$110

Aug-27-20

Initiated

Citigroup

Buy

$112

Jan-08-20

Initiated

Goldman

Neutral

$35

Sep-26-19

Initiated

BofA/Merrill

Buy

$34

Sep-12-19

Initiated

Guggenheim

Buy

Aug-14-19

Upgrade

BMO Capital Markets

Market Perform → Outperform

$29 → $36

May-01-19

Upgrade

Citigroup

Neutral → Buy

$21 → $32

Mar-08-19

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$32

Nov-15-18

Downgrade

Mizuho

Buy → Neutral

Jun-27-18

Downgrade

Citigroup

Buy → Neutral

Jan-12-18

Upgrade

Mizuho

Neutral → Buy

$12 → $18

Sep-28-17

Initiated

Goldman

Buy

$16

Jun-16-17

Initiated

Cantor Fitzgerald

Overweight

$13

May-24-22 08:00AM	Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology Business Wire
May-17-22 08:00AM	Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata Business Wire
May-16-22 09:00AM	Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups Business Wire
May-11-22 09:02AM	Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomens Association 2022 Rising Star Business Wire
08:30AM	Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On Business Wire
May-09-22 04:44PM	Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership Business Wire
May-07-22 08:08AM	Horizon Therapeutics Public Limited Company Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year Simply Wall St.
May-04-22 07:00AM	Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results Business Wire
May-03-22 11:40AM	HZNP or TECH: Which Is the Better Value Stock Right Now? Zacks
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick Zacks
09:15AM	Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis Business Wire
May-02-22 04:05PM	Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community Business Wire
01:00AM	Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
Apr-27-22 08:01AM	Horizon Therapeutics plc Among Top Companies for Overall Corporate Reputation in 2021 Global PatientView Survey of Patient Groups Worldwide Business Wire
Apr-19-22 09:00AM	Horizon Therapeutics and Massachusetts Institute of Technology (MIT) Solve Announce Second Annual Horizon Prize to Inspire Solutions that Improve the Quality of Life for the Global Rare Disease Community Business Wire
Apr-18-22 01:12PM	Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) Stock's On An Uptrend: Are Strong Financials Guiding The Market? Simply Wall St.
Apr-14-22 08:00AM	Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022 Business Wire
Apr-11-22 09:20AM	Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For® Business Wire
Mar-31-22 08:30AM	New Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
Mar-24-22 04:00AM	Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland Business Wire
Mar-21-22 02:51PM	Biotech Stock Near Buy Point After Positive Earnings; Is It Worth Considering? Investor's Business Daily
Mar-18-22 09:16AM	Horizon Therapeutics USA, Inc. -- Moody's upgrades Horizon Therapeutics to Ba1; stable outlook Moody's
09:02AM	Horizon Therapeutics USA, Inc. -- Moody's upgrades Horizon Therapeutics to Ba1; stable outlook Moody's
Mar-07-22 08:00AM	Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living With Uncontrolled Gout Business Wire
Mar-04-22 08:48AM	Here's Why I Think Horizon Therapeutics (NASDAQ:HZNP) Might Deserve Your Attention Today Simply Wall St.
Mar-02-22 08:00AM	Horizon Therapeutics plc Partners with Christine Ha, First Blind Contestant and Winner of MasterChef, to Amplify Her Unstoppable NMOSD Story Business Wire
Mar-01-22 07:00AM	Horizon Therapeutics plc Reports Fourth-Quarter 2021 and Full-Year 2021 Financial Results; Announces Full-Year 2022 Guidance Business Wire +6.47%
Feb-28-22 11:29AM	Horizon Therapeutics plc Launches #RAREis Representation Program to Elevate Global Rare Disease Equity Business Wire
Feb-23-22 08:00AM	Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED) Business Wire
Feb-21-22 04:05PM	Horizon Therapeutics plc to Present at the Cowen and Company 42nd Annual Health Care Conference Business Wire
Feb-16-22 08:15AM	Horizon Therapeutics plc Names Sean Clayton Executive Vice President and General Counsel Business Wire
08:00AM	New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
Feb-15-22 11:00AM	New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations Business Wire
09:00AM	Horizon Therapeutics plc Partners with the Doug the Pug Foundation and Sing Me A Story Foundation to Bring Awareness to Rare Diseases Impacting Children through #RAREis Playlist Business Wire
Feb-10-22 08:00AM	Horizon Therapeutics plc Named Title Partner of the Irish Open Business Wire
Feb-07-22 06:38PM	Formidable Asset Management, LLC Buys Flux Power Holdings Inc, BP PLC, BHP Group, Sells Eaton ... GuruFocus.com
08:00AM	Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2021 Financial Results and Host Webcast on March 1, 2022 Business Wire
Feb-04-22 01:38PM	Cannon Global Investment Management, LLC Buys BHP Group, SPDR S&P Regional Banking ETF, ... GuruFocus.com
Feb-02-22 05:38PM	WP Advisors, LLC Buys PayPal Holdings Inc, Booking Holdings Inc, Uber Technologies Inc, Sells ... GuruFocus.com
05:38PM	Chase Investment Counsel Corp Buys Eagle Materials Inc, National Fuel Gas Co, AbbVie Inc, Sells ... GuruFocus.com
11:10AM	Were Hedge Funds Right About Horizon Therapeutics Public Limited Company (HZNP)? Insider Monkey
Jan-24-22 08:00AM	Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Business Wire
Jan-19-22 09:38AM	Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ... GuruFocus.com
Jan-18-22 06:35AM	Even though Horizon Therapeutics (NASDAQ:HZNP) has lost US$862m market cap in last 7 days, shareholders are still up 453% over 5 years Simply Wall St.
Jan-11-22 07:45AM	ACELYRIN Appoints Melanie Gloria as Chief Operating Officer PR Newswire
Jan-10-22 07:30AM	Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout Business Wire
Jan-07-22 08:20AM	Horizon Therapeutics signs lease for big expansion in Montgomery County American City Business Journals
Jan-06-22 08:00AM	Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability Business Wire
Dec-23-21 08:00AM	Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire
Dec-20-21 01:34PM	Russian With Kremlin Ties Charged With Hacking for Inside Trades Bloomberg
Dec-16-21 08:00AM	Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases Business Wire
Dec-08-21 06:38PM	Inv Corp All America Buys Zuora Inc, Ollie's Bargain Outlet Holdings Inc, Graco Inc, Sells ... GuruFocus.com
Dec-07-21 02:30PM	Hedge Funds Are Piling Into Horizon Therapeutics (HZNP) Insider Monkey
Dec-02-21 09:00AM	Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Tills Home into a Museum and Theater Business Wire
08:30AM	Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List Business Wire
Dec-01-21 01:30AM	Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education Business Wire
Nov-22-21 10:13AM	Goldman Sachs 3 Stock Picks With Over 50% Upside Potential TipRanks
08:00AM	New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
Nov-19-21 07:28AM	Are Institutions Heavily Invested In Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) Shares? Simply Wall St.
Nov-15-21 09:00AM	Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative Business Wire
Nov-12-21 08:33AM	New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED) Business Wire
07:29AM	Horizon Therapeutics plc Receives CHMP Positive Opinion for UPLIZNA® (inebilizumab) as a Monotherapy for the Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
Nov-09-21 08:00AM	Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis Business Wire
Nov-08-21 04:05PM	Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire
Nov-07-21 12:57PM	Dov Gertzulins DG Capital Portfolio: Top 10 Stocks Insider Monkey
Nov-05-21 09:01AM	Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco Business Wire
Nov-04-21 01:00PM	Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week Business Wire
Nov-03-21 05:00PM	Horizon Pharma plc (HZNP) Q3 2021 Earnings Call Transcript Motley Fool
12:55PM	Horizon CEO: Growth Driver Tepezza 'Still At A Fraction' Of Expected Peak Sales Investor's Business Daily Video
07:02AM	Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan Business Wire
07:00AM	Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance Business Wire
Nov-02-21 10:00AM	Horizon Therapeutics (HZNP) is a Top-Ranked Momentum Stock: Should You Buy? Zacks
Nov-01-21 11:05AM	Were Hedge Funds Right About Horizon Therapeutics (HZNP)? Insider Monkey
10:00AM	New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizons Commitment to Improving Outcomes for People Living with Uncontrolled Gout Business Wire
Oct-27-21 08:30AM	If You Invested $1000 in Horizon Therapeutics 10 Years Ago, This Is How Much You'd Have Now Zacks
Oct-25-21 08:00AM	MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate Business Wire
Oct-22-21 09:29AM	Horizon Therapeutics plc Named to Newsweeks List of the Most Loved Workplaces for 2021 Business Wire
Oct-21-21 12:00PM	Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED) Business Wire
Oct-15-21 08:49AM	10 Best Biotech Stocks to Buy According to Joseph Edelmans Perceptive Advisors Insider Monkey
Oct-13-21 08:00AM	New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
Oct-12-21 09:00AM	New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting Business Wire
Oct-11-21 09:00AM	The Zacks Rank Explained: How to Find Strong Buy Medical Stocks Zacks
08:30AM	Here's How Much a $1000 Investment in Horizon Therapeutics Made 10 Years Ago Would Be Worth Today Zacks
08:00AM	Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021 Business Wire
Oct-06-21 08:00AM	Horizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption Business Wire
Oct-04-21 08:30AM	New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
08:00AM	Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2021 Business Wire
Sep-29-21 07:00AM	Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day Business Wire
Sep-28-21 09:14AM	Do Hedge Funds Love Horizon Therapeutics Public Limited Company (HZNP)? Insider Monkey
Sep-23-21 09:00AM	Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021 Business Wire
08:30AM	Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
Sep-21-21 08:00AM	Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Rare Disease Diagnosis Business Wire
07:30AM	HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline PR Newswire
Sep-16-21 09:00AM	Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women by Fortune and Great Place to Work® Business Wire
Sep-07-21 08:30AM	Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED) Business Wire
Sep-06-21 07:55AM	Are Strong Financial Prospects The Force That Is Driving The Momentum In Horizon Therapeutics Public Limited Company's NASDAQ:HZNP) Stock? Simply Wall St.
Sep-01-21 09:10AM	Horizon Therapeutics plc Named One of PEOPLEs 100 Companies That Care® Business Wire
Aug-31-21 01:25PM	15 Best Pharmaceutical Stocks to Invest In Insider Monkey
Aug-23-21 04:01PM	Horizon Therapeutics plc to Participate in Upcoming Conferences Business Wire
Aug-04-21 07:00AM	Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance Business Wire +7.77%

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Walbert Timothy P	Chairman, President and CEO	May 20	Option Exercise	22.14	25,000	553,500	485,549	May 20 06:15 PM
Walbert Timothy P	Chairman, President and CEO	May 20	Sale	90.00	25,000	2,250,000	460,549	May 20 06:15 PM
Walbert Timothy P	Chairman, President and CEO	May 11	Option Exercise	22.14	17,600	389,664	478,149	May 13 04:31 PM
Walbert Timothy P	Chairman, President and CEO	May 11	Sale	90.00	17,600	1,584,000	460,549	May 13 04:31 PM
Walbert Timothy P	Chairman, President and CEO	May 06	Option Exercise	22.14	7,400	163,836	467,949	May 10 05:59 PM
Walbert Timothy P	Chairman, President and CEO	May 06	Sale	90.86	7,400	672,342	460,549	May 10 05:59 PM
Walbert Timothy P	Chairman, President and CEO	May 02	Sale	96.04	25,000	2,401,006	460,549	May 04 04:24 PM
Walbert Timothy P	Chairman, President and CEO	Apr 22	Option Exercise	22.14	25,000	553,500	510,549	Apr 22 06:49 PM
Walbert Timothy P	Chairman, President and CEO	Apr 22	Sale	106.59	25,000	2,664,632	485,549	Apr 22 06:49 PM
Hoelscher Paul W.	EVP, CFO	Apr 20	Option Exercise	22.14	50,000	1,107,000	51,049	Apr 22 06:47 PM
Hoelscher Paul W.	EVP, CFO	Apr 20	Sale	114.71	50,000	5,735,449	1,049	Apr 22 06:47 PM
Thompson Elizabeth H.Z.	EVP, Research & Development	Apr 18	Sale	115.64	8,098	936,453	13,058	Apr 20 04:13 PM
DesJardin Michael A.	EVP, Technical Operations	Apr 12	Sale	113.12	20,214	2,286,703	82,346	Apr 14 04:49 PM
Walbert Timothy P	Chairman, President and CEO	Apr 08	Option Exercise	22.14	25,000	553,500	510,549	Apr 08 04:11 PM
Walbert Timothy P	Chairman, President and CEO	Apr 08	Sale	112.38	25,000	2,809,521	485,549	Apr 08 04:11 PM
Hoelscher Paul W.	EVP, CFO	Apr 06	Option Exercise	21.27	215,335	4,580,417	216,384	Apr 08 04:09 PM
Hoelscher Paul W.	EVP, CFO	Apr 06	Sale	110.01	91,710	10,089,026	66,673	Apr 08 04:09 PM
Hoelscher Paul W.	EVP, CFO	Apr 06	Sale	110.01	215,335	23,688,788	1,049	Apr 08 04:09 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Apr 06	Sale	110.02	42,009	4,621,872	10,629	Apr 08 04:07 PM
Walbert Timothy P	Chairman, President and CEO	Mar 30	Sale	105.26	50,000	5,262,787	485,549	Apr 01 04:10 PM
Walbert Timothy P	Chairman, President and CEO	Mar 25	Option Exercise	22.14	25,000	553,500	560,549	Mar 25 06:40 PM
Walbert Timothy P	Chairman, President and CEO	Mar 25	Sale	109.37	25,000	2,734,340	535,549	Mar 25 06:40 PM
Hoelscher Paul W.	EVP, CFO	Mar 25	Sale	110.00	663	72,930	158,383	Mar 25 06:38 PM
Hoelscher Paul W.	EVP, CFO	Mar 24	Sale	110.00	1,481	162,910	159,046	Mar 25 06:38 PM
Hoelscher Paul W.	EVP, CFO	Mar 23	Option Exercise	15.96	26,090	416,396	27,139	Mar 25 06:38 PM
Hoelscher Paul W.	EVP, CFO	Mar 23	Sale	110.01	11,699	1,287,018	160,527	Mar 25 06:38 PM
Hoelscher Paul W.	EVP, CFO	Mar 23	Sale	110.00	26,090	2,870,002	1,049	Mar 25 06:38 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Mar 18	Option Exercise	22.14	8,531	188,876	52,638	Mar 21 04:25 PM
Walbert Timothy P	Chairman, President and CEO	Mar 11	Option Exercise	22.14	25,000	553,500	560,549	Mar 11 05:17 PM
Walbert Timothy P	Chairman, President and CEO	Mar 11	Sale	100.93	25,000	2,523,314	535,549	Mar 11 05:17 PM
DesJardin Michael A.	EVP, Technical Operations	Mar 02	Sale	97.19	35,000	3,401,752	102,560	Mar 04 04:19 PM
Pasternak Andy	EVP and Chief Business Officer	Feb 18	Sale	94.82	1,313	124,499	39,659	Feb 18 04:42 PM
Walbert Timothy P	Chairman, President and CEO	Feb 11	Option Exercise	22.14	25,000	553,500	610,549	Feb 11 04:16 PM
Walbert Timothy P	Chairman, President and CEO	Feb 11	Sale	97.41	25,000	2,435,242	585,549	Feb 11 04:16 PM
Walbert Timothy P	Chairman, President and CEO	Feb 01	Option Exercise	0.00	9,087	0	44,690	Feb 02 04:25 PM
Walbert Timothy P	Chairman, President and CEO	Jan 31	Sale	91.85	100,000	9,184,983	585,549	Jan 31 05:26 PM
Walbert Timothy P	Chairman, President and CEO	Jan 28	Option Exercise	22.14	25,000	553,500	710,549	Jan 31 05:26 PM
Walbert Timothy P	Chairman, President and CEO	Jan 28	Sale	90.00	25,000	2,250,000	685,549	Jan 31 05:26 PM
DesJardin Michael A.	EVP, Technical Operations	Jan 21	Option Exercise	0.00	3,679	0	139,385	Jan 24 05:07 PM
Hoelscher Paul W.	EVP, CFO	Jan 21	Option Exercise	0.00	5,558	0	70,138	Jan 24 05:06 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Jan 21	Option Exercise	0.00	5,354	0	61,665	Jan 24 05:05 PM
Walbert Timothy P	Chairman, President and CEO	Jan 21	Option Exercise	0.00	20,336	0	694,558	Jan 24 05:04 PM
Walbert Timothy P	Chairman, President and CEO	Jan 14	Option Exercise	22.14	25,000	553,500	699,222	Jan 14 06:44 PM
Walbert Timothy P	Chairman, President and CEO	Jan 14	Sale	90.02	25,000	2,250,412	674,222	Jan 14 06:44 PM
Pasternak Andy	EVP and Chief Business Officer	Jan 06	Sale	99.57	7,987	795,296	40,972	Jan 06 09:02 PM
Walbert Timothy P	Chairman, President and CEO	Dec 31	Option Exercise	22.14	25,000	553,500	529,482	Jan 04 05:00 PM
Walbert Timothy P	Chairman, President and CEO	Dec 31	Sale	108.07	75,000	8,105,487	454,482	Jan 04 05:00 PM
Hoelscher Paul W.	EVP, CFO	Dec 28	Option Exercise	15.96	8,575	136,857	9,624	Dec 30 09:00 PM
Hoelscher Paul W.	EVP, CFO	Dec 28	Sale	110.00	8,575	943,250	1,049	Dec 30 09:00 PM
Pasternak Andy	EVP and Chief Business Officer	Dec 07	Sale	100.00	1,525	152,500	21,830	Dec 08 06:35 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	Dec 01	Option Exercise	22.14	79,484	1,759,776	116,005	Dec 03 05:20 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	Dec 01	Sale	106.62	79,484	8,474,584	36,521	Dec 03 05:20 PM
Walbert Timothy P	Chairman, President and CEO	Nov 30	Sale	102.40	50,000	5,119,881	504,482	Dec 01 05:58 PM
MOZE BARRY	EVP, Chief Admin. Officer	Nov 04	Option Exercise	14.77	75,743	1,118,556	151,424	Nov 05 05:00 PM
Pasternak Andy	EVP and Chief Business Officer	Nov 04	Option Exercise	29.52	23,251	686,370	53,523	Nov 05 05:00 PM
MOZE BARRY	EVP, Chief Admin. Officer	Nov 04	Sale	112.28	75,743	8,504,208	75,681	Nov 05 05:00 PM
Pasternak Andy	EVP and Chief Business Officer	Nov 04	Sale	113.04	30,168	3,410,181	23,355	Nov 05 05:00 PM
Walbert Timothy P	Chairman, President and CEO	Nov 01	Sale	118.49	25,000	2,962,327	554,482	Nov 03 04:30 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Oct 27	Option Exercise	7.61	10,729	81,648	19,844	Oct 29 04:55 PM
Walbert Timothy P	Chairman, President and CEO	Sep 30	Sale	110.30	50,000	5,515,140	579,482	Oct 01 04:08 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Sep 21	Option Exercise	7.61	46,271	352,122	55,386	Sep 23 05:00 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Sep 21	Sale	110.00	46,271	5,089,810	9,115	Sep 23 05:00 PM
Beeler Brian K	EVP, General Counsel	Sep 17	Sale	107.91	28,143	3,036,911	62,775	Sep 17 05:06 PM
Pasternak Andy	EVP and Chief Business Officer	Sep 09	Option Exercise	29.52	23,250	686,340	46,604	Sep 13 08:00 PM
Pasternak Andy	EVP and Chief Business Officer	Sep 09	Sale	107.84	23,250	2,507,261	23,354	Sep 13 08:00 PM
Walbert Timothy P	Chairman, President and CEO	Aug 27	Option Exercise	22.14	7,435	164,611	847,723	Aug 27 05:00 PM
Beeler Brian K	EVP, General Counsel	Aug 16	Option Exercise	22.14	65,857	1,458,074	165,816	Aug 17 05:01 PM
Beeler Brian K	EVP, General Counsel	Aug 16	Sale	106.00	74,898	7,939,188	90,918	Aug 17 05:01 PM
Thompson Elizabeth H.Z.	EVP, Research & Development	Aug 05	Sale	106.34	7,542	802,025	14,187	Aug 06 05:03 PM
Walbert Timothy P	Chairman, President and CEO	Jul 30	Sale	101.74	25,000	2,543,489	840,288	Jul 30 04:28 PM
GREY MICHAEL G	Director	Jul 22	Option Exercise	2.37	5,000	11,850	5,000	Jul 23 05:00 PM
GREY MICHAEL G	Director	Jul 22	Sale	100.04	5,000	500,200	0	Jul 23 05:00 PM
MOZE BARRY	EVP, Chief Admin. Officer	Jul 08	Sale	92.54	35,076	3,246,012	71,639	Jul 09 05:00 PM
Walbert Timothy P	Chairman, President and CEO	Jun 01	Sale	91.85	25,000	2,296,204	875,887	Jun 03 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience